TL;DR: No head-to-head trial of retatrutide and orforglipron exists; TRIUMPH-1 and ATTAIN-1 differ in design, duration and estimand, so cross-trial gaps mislead.
Retatrutide vs Orforglipron: Why Cross-Trial Comparisons Mislead
Has Retatrutide Been Compared Directly With Orforglipron?
No. In the sources reviewed for this guide, no randomised trial pits retatrutide (LY3437943) against orforglipron (Foundayo), and none appears in the TRIUMPH-1 registry record.[1][2] Both are Eli Lilly molecules, so side-by-side tables circulate readily online. They are assembled from separate trials and are not a controlled comparison. This guide explains why, as general trial methodology for researchers reading the literature.
Retatrutide is covered in our wider retatrutide research guide and on the research-grade retatrutide product page. Orforglipron is not part of Velox’s reagent range.
How Do the Two Molecules Differ Pharmacologically?
Retatrutide is an investigational injectable peptide that engages three receptors: GIP, GLP-1 and glucagon.[1] Orforglipron is a non-peptide, orally available small molecule that targets the GLP-1 receptor alone.[3] The difference is categorical rather than a matter of degree: a different chemical class, route of administration and receptor profile. Our explainer Is retatrutide a GLP-1? sets out why that label is incomplete for a multi-receptor agonist, and the mechanism of action guide covers the receptor pharmacology.
How Do the TRIUMPH-1 and ATTAIN-1 Designs Differ?
TRIUMPH-1 (NCT05929066) randomised 2,339 adults to retatrutide 4, 9 or 12 mg or placebo, with an 80-week primary period, and was published in the New England Journal of Medicine on 29 September 2026.[1] ATTAIN-1 randomised 3,127 adults to orforglipron 6, 12 or 36 mg or placebo for 72 weeks.[3]
| Feature | TRIUMPH-1 | ATTAIN-1 |
|---|---|---|
| Investigational agent | Retatrutide (injectable peptide) | Orforglipron (oral small molecule) |
| Participants randomised | 2,339 | 3,127 |
| Dose arms | 4, 9, 12 mg | 6, 12, 36 mg |
| Primary period | 80 weeks | 72 weeks |
| Regulatory status | Investigational | Licensed by the MHRA (10 Aug 2026); EMA CHMP positive opinion (15 Oct 2026) |
Duration alone matters: effects in long-running trials are time-dependent, so a 72-week and an 80-week value are not measured at the same point on the curve. Enrolment criteria, baseline characteristics and the intensity of any background lifestyle support also differ by protocol and should be checked in each paper. We deliberately do not tabulate outcome percentages here, because placing them side by side is exactly the comparison this guide cautions against.
Why Do Estimands Make Cross-Trial Reading Harder?
The ICH E9(R1) framework asks trialists to define the estimand: the precise question an analysis answers. TRIUMPH-1 reports results under both a treatment-regimen estimand (all randomised participants, regardless of adherence) and an efficacy estimand (as if treatment were taken as intended).[1] Our TRIUMPH-1 NEJM guide explains the distinction. A reader who sets one trial’s efficacy-estimand figure beside another trial’s treatment-regimen figure is comparing answers to different questions. Even when estimands match, handling of missing data after treatment discontinuation can differ between statistical analysis plans.
What Is the Regulatory Status of Each Programme?
The MHRA authorised Foundayo on 10 August 2026, and the EMA’s CHMP adopted a positive opinion on 15 October 2026, with the European Commission decision pending at that point.[4] See our summaries of the MHRA decision and the CHMP opinion. Retatrutide has no marketing authorisation anywhere; Lilly has described a planned US submission in the first quarter of 2027.[5]
How Does Licensed Pharma Development Differ From Research-Use Compounds?
Both programmes are regulated clinical development by a licensed pharmaceutical sponsor, with registered protocols, ethics oversight and medical supervision of participants. Their results do not transfer to a laboratory reagent. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent and reports trial news only as third-party information for researchers. See the research-grade retatrutide page for specifications.
This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med, 29 September 2026. nejm.org
- ClinicalTrials.gov. TRIUMPH-1, NCT05929066. clinicaltrials.gov
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med, doi:10.1056/NEJMoa2511774. nejm.org
- UK Government (MHRA). “UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.” August 2026. gov.uk. CHMP opinion reported by Pharmaceutical Executive, 16 October 2026.
- Eli Lilly and Company. Third-quarter 2026 financial results (Form 8-K), 29 October 2026. sec.gov
Frequently Asked Questions
Has retatrutide been compared directly with orforglipron?
No head-to-head trial of the two has been reported in the sources reviewed for this guide. Any side-by-side figures come from separate trials with different protocols, populations and durations, and are not a controlled comparison.
Why can't TRIUMPH-1 and ATTAIN-1 be compared directly?
The trials differed in populations, dose ranges, treatment duration (80 weeks versus 72 weeks) and statistical estimands. Without randomisation between the two drugs, differences can reflect design rather than pharmacology.
What is an estimand, and why does it matter here?
An estimand, defined in the ICH E9(R1) framework, states exactly which question a trial analysis answers, for example effects regardless of adherence versus effects under treatment as intended. Comparing one trial's treatment-regimen result with another's efficacy result is a category error.
How do the two molecules differ pharmacologically?
Retatrutide is an investigational injectable peptide acting at GIP, GLP-1 and glucagon receptors. Orforglipron is an orally available, non-peptide small molecule that acts at the GLP-1 receptor. Their chemistry and receptor profiles are distinct.
Is retatrutide approved, and does this apply to research-use material?
No. Retatrutide is investigational with no marketing authorisation. Licensed trial data do not transfer to laboratory reagents. Velox Peptides supplies retatrutide only as an in vitro research reagent, with no therapeutic claims.